A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Nature Medicine2009Vol. 15(1), pp. 68–74
Citations Over TimeTop 1% of 2009 papers
Pierre Farmer, Hervé Bonnefoi, Pascale Anderle, David Cameron, P. Wirapati, Véronique Becette, Sylvie André, Martine Piccart, Mario Campone, Étienne Brain, Gaëtan MacGrogan, Thierry Petit, Jacek Jassem, Frédéric Bibeau, Emmanuel Blot, Jan Bogaerts, Michel Aguet, Jonas Bergh, Richard Iggo, Mauro Delorenzi
Related Papers
- → A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.(1991)83 cited
- → Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model(1996)15 cited
- → Intravesical epirubicin in the prophylaxis of superficial bladder cancer(1996)6 cited
- → Stability of intravesical epirubicin infusion: a sequential temperature study(2003)5 cited
- Optimal Ratio of Lipiodol to Epirubicin for Chemotherapeutic Emulsion Preparation: An Experimental Study(2004)